On August 14th, KTB Investment & Securities researcher Kang Ha-young stated, "1) From August, the global number of COVID-19 confirmed cases appears to have stabilized, and considering reagent export data and supply competition, there is a high possibility that 2Q quarterly earnings have peaked. 2) The stock price, which has surged nearly 800% year-to-date, may lead to deteriorating investor sentiment if COVID-19 vaccine and treatment development results are confirmed, so caution is needed." He set Seegene's target price at 230,000 KRW.
Over the past five days, individual investors have net purchased 278,919 shares of Seegene, while foreigners and institutions have net sold 168,201 shares and 112,221 shares, respectively.

※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

